- Projects & figures
- News & Events
- Managing your project
- About ERC
In 2012, 2.8 million people in the EU were diagnosed with cancer. It is the second most common cause of death in the Union – three out of 10 deaths for men, and two out of 10 deaths for women – a figure that is expected to rise due to the ageing European population. Dr Danijela Matic Vignjevic’s STARLIN project is using ERC funding to understand how normal cells become cancerous and spread.
Significant progress has been made in understanding breast tumour biology. However statistics indicate that the number of breast cancer patients and victims will continue to increase. Dr. Bentires-Alj, ERC Starting Grantee at the Friedrich Miescher Institute for Biomedical Research in Basel, and his team are studying the roles of the still under-explored family of protein-tyrosine phosphatases (PTPs) in both normal breast development and cancers. In a recent study, published in Nature Medicine in March 2012, Dr Bentires-Alj's team have revealed the fundamental role of the protein phosphatase SHP2 in breast cancer proliferation, invasion and metastasis.